Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study

Inclusion Criteria: * Age ≥ 18 years * WHO PS 0-2 * Histological or cytological confirmation of non-small cell lung cancer or an 18F-FDG-positive, growing mass on CT-thorax suggestive of NSCLC. * Stage IIIA or IIIB * Patients with extensive mediastinal lymph node involvement (such as N3), or large primary tumour size * Adequate pulmonary function estimated by flow volume curves * Life expectancy of at least 6 months * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial. * Planned for 25 x 2.4 Gy, with concomitant chemotherapy * Before patient registration, written informed consent will be obtained. Exclusion Criteria: * Presence of contra-indications for undergoing MRI